Author

Young-Ho Kim

Institutions: Samsung Medical Center, Sungkyunkwan University

Observed institutions: Samsung Medical Center, Sungkyunkwan University

ORCID: 0000-0003-1803-2513

Observed ORCIDs: 0000-0003-1803-2513, 0000-0001-8713-0753

OpenAlex ID: A5113970375

Risankizumab for Ulcerative Colitis

2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

2021 · Laurent Peyrin-Biroulet, Ailsa Hart, et al. · The Lancet. Gastroenterology & hepatology · 97

The effect of sildenafil on lower esophageal sphincter and body motility in normal male adults

2001 · Poong-Lyul Rhee, Jae Geun Hyun, et al. · The American Journal of Gastroenterology · 37

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

2022 · Jihye Park, Jae Hee Cheon, et al. · Gut and Liver · 8

Prediction of infliximab and anti-drug antibody concentrations in patients with inflammatory bowel disease using machine learning models with real-world data from a prospective cohort study

2026 · Minjung Kim, Minjung Kim, et al. · Frontiers in Pharmacology · 1

Real-world effectiveness and safety of upadacitinib in Korean patients with inflammatory bowel disease: a single-center retrospective study

2026 · Ji Eun Kim, Yeong Chan Lee, et al. · Intestinal Research

Works count: 6

Citation count: 277

H-index: 4

I10-index: 3